Synthesis and evaluation of mitochondria-targeted multi-gated therapeutics (theranostics) for tumor suppression in vivo: An approach to prospective preclinical benefit
Implementing Organization
Principal Investigator
Dr. Sankarprasad Bhuniya
JIS University, Kolkata, West Bengal
About
Prehistorical cancer disease remains a burden for modern society. It remains a challenging puzzle in the modern healthcare system. Chemotherapy, radiotherapy, and surgical resection are widely used against cancer for relieving it. However, the activity of those against cancer is still hindered due to undesired cytotoxicity to neighboring normal cells and tissues. Therefore, a remedy is always in search that can offer a new protocol to gain maximum clinical benefit within a short time with minimal side effects. one such type of attractive strategy in prognostic assessment is theranostic -modern technology can serve both as a diagnosis and therapy. Usually, cancers are of various types with heterogeneity, making them resistant to chemotherapy. Thus, it is to be believed that multi-parametric drugs/prodrugs could be an ideal solution to suppress cancer growth. The mitochondria are the home of ATP energy. The ATP energy is propagated manyfold in cancer cells. On the other hand, this DNA-containing organelle participates in the apoptotic pathway of cell death via releasing of cytochrome C. Thus, disrupting the function of mitochondria selectively in cancer cells could be the ideal strategy to fight against cancer. In this context, a series of new molecules will be developed that will selectively enter cancer cells and subsequently be activated in cancer cells upon encountering overexpressed unusual entities/various prognostic factors. The developing protonophore (pKa 4.5) can reduce ATP synthesis by disrupting inner mitochondrial membrane potential (MEM); in addition to that, its self-aggregation may produce ROS via NIR light-induced hyperthermia. Indeed, photoacoustic/ NIR imaging allows us to read out the activity of the multi-gated therapeutics in vivo to provide summarized preclinical information.
Source
Source
Anusandhan National Research Foundation/Science and Engineering Research Board (SERB), DST 2023-24
Science and Engineering Research Board (SERB), New Delhi
Anusandhan National Research Foundation (ANRF)
Quick Information
Area of Research
Chemical Sciences
Start Year
2024
End Year
2027
Sanction Amount
₹ 42.94 L
Status
Ongoing
Contact
spbhuniya@jisiasr.org
Output
No. of Research Paper
00
Technologies (If Any)
00
No. of PhD Produced
00
No. of Patents
Filed :00
Grant :00
Disclaimer:
Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.
Please enter your details
Please provide your name and email to continue. Your details are saved in this browser for future use.
Latest Updates
Loading…
⚠️
You are leaving this website
You are about to be redirected to an external website that is not operated by
India Science, Technology & Innovation (ISTI) Portal.